Page 204 - 18F-FDG PET as biomarker in aggressive lymphoma; technical and clinical validation

Chapter 7
Table S2. Continued
39 yes
40 yes
41 yes
42 yes
43 yes
44 yes
45 yes
46 yes
47 yes
48 yes
49 yes
50 yes
51 yes
52 yes
53 yes
54 yes
55 yes
56 yes
57 yes
58 yes
59 yes
60 yes
61 yes
62 yes
63 yes
64 no
65 yes
66 yes
67 yes
68 yes
69 yes
70 yes
71 yes
72 yes
73 yes
74 yes
75 yes
76 yes
Immunohistochemistry
1 0 0 0 1 1 1 1 1 1 1 1 0 0 1 1 1 1 1 1 1 0 9 0 1 1 9 1 9 9 1 0 1 1 1
1 1 0 1 1 1 1 9 1 1 1 1 1 9 9
1 1 9 1 1 1 1 1 1 1 1 1 1 9 1 1 1 1 0 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 0 1 9 9 1 1 1 1 1 1 1 1 1 0 1 1 9 1 1 1 1 1 1 0
1 1 9 9 9 1 9 1 1 1 1 1 9 1 1 1 9 9 1 9
1 1 9 9 0 1 1 1 1 9 1 1 1 1 1 1 1 0 0 1 1 0 9 1 1 1 1 1 1 1 1 1 1 9 9 1 0 1 1 1
Patient number
Eligible
CD20
0= negative (<95%), 1=positive (>95%)
BCL2 0=negative (<50%), 1=positive (50%), 9=not available
MYC-IHC 0=negative (<40%), 1=positive (>40%), 9=not available
CD10 0=negative, 1=positive, 9=not available
BCL6 0=negative (<40%), 1=positive (>40%), 9=not available
202